$elv 2017 Q1 10-Q

Concept	2017 Q1	2016 Q1
Revenue	$22.53B	$20.29B
YoY Change	11.02%	6.49%
Cost Of Revenue	$17.54B	$15.54B
YoY Change	12.9%	9.99%
Gross Profit	$4.982B	$4.750B
YoY Change	4.9%	-3.55%
Gross Profit Margin	22.12%	23.41%
Selling, General & Admin	$3.191B	$3.200B
YoY Change	-0.28%	1.75%
% of Gross Profit	64.05%	67.38%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$27.30M	$25.60M
YoY Change	6.64%	1.99%
% of Gross Profit	0.55%	0.54%
Operating Expenses	$3.191B	$3.200B
YoY Change	-0.28%	1.75%
Operating Profit	$1.585B	$1.570B
YoY Change	0.96%	-0.56%
Interest Expense	$235.0M	$187.1M
YoY Change	25.6%	21.18%
% of Operating Profit	14.82%	11.91%
Other Income/Expense, Net
YoY Change
Pretax Income	$1.514B	$1.312B
YoY Change	15.4%	-16.39%
Income Tax	$505.1M	$609.0M
% Of Pretax Income	33.36%	46.42%
Net Earnings	$1.009B	$703.0M
YoY Change	43.53%	-18.75%
Net Earnings / Revenue	4.48%	3.47%
Basic Earnings Per Share	$3.82	$2.69
Diluted Earnings Per Share	$3.73	$2.63
COMMON SHARES
Basic Shares Outstanding	264.4M shares	261.8M shares
Diluted Shares Outstanding	270.4M shares	267.5M shares

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.72B	$20.03B
YoY Change	23.42%	-0.84%
Cash & Equivalents	$6.772B	$1.676B
Short-Term Investments	$17.95B	$18.36B
Other Short-Term Assets	$1.824B	$2.494B
YoY Change	-26.88%	-1.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$37.98B	$32.97B
YoY Change	15.22%	-5.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.958B	$1.998B
YoY Change	-2.04%	4.3%
Goodwill	$17.56B	$17.56B
YoY Change	-0.01%	-0.05%
Intangibles	$7.923B	$8.108B
YoY Change	-2.28%	-2.24%
Long-Term Investments	$22.66B	$22.58B
YoY Change	0.35%	-2.71%
Other Assets	$640.5M	$609.8M
YoY Change	5.03%	-18.26%
Total Long-Term Assets	$30.96B	$30.89B
YoY Change	0.22%	0.29%
TOTAL ASSETS
Total Short-Term Assets	$37.98B	$32.97B
Total Long-Term Assets	$30.96B	$30.89B
Total Assets	$68.94B	$63.86B
YoY Change	7.96%	-2.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.622B	$4.165B
YoY Change	-13.04%	-6.51%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$540.0M	$540.0M
YoY Change	0.0%	20.0%
Long-Term Debt Due	$1.153B	$399.2M
YoY Change	188.78%	-36.13%
Total Short-Term Liabilities	$23.17B	$20.81B
YoY Change	11.36%	-2.32%
LONG-TERM LIABILITIES
Long-Term Debt	$15.45B	$14.86B
YoY Change	3.94%	0.68%
Other Long-Term Liabilities	$889.9M	$1.320B
YoY Change	-32.58%	20.06%
Total Long-Term Liabilities	$16.34B	$16.18B
YoY Change	0.96%	2.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.17B	$20.81B
Total Long-Term Liabilities	$16.34B	$16.18B
Total Liabilities	$42.85B	$40.31B
YoY Change	6.3%	-2.18%
SHAREHOLDERS EQUITY
Retained Earnings	$17.36B	$15.31B
YoY Change	13.37%	8.2%
Common Stock	$2.600M	$2.600M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.09B	$23.55B
YoY Change
Total Liabilities & Shareholders Equity	$68.94B	$63.86B
YoY Change	7.96%	-2.57%

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$1.009B	$703.0M
YoY Change	43.53%	-18.75%
Depreciation, Depletion And Amortization	$27.30M	$25.60M
YoY Change	6.64%	1.99%
Cash From Operating Activities	$2.688B	$1.360B
YoY Change	97.69%	-17.61%
INVESTING ACTIVITIES
Capital Expenditures	$127.9M	$117.5M
YoY Change	8.85%	32.32%
Acquisitions	$0.00	$0.00
YoY Change		-100.0%
Other Investing Activities	-$11.80M	$0.00
YoY Change
Cash From Investing Activities	-$1.227B	-$1.391B
YoY Change	-11.79%	-48.7%
FINANCING ACTIVITIES
Cash Dividend Paid	$172.0M	$170.7M
YoY Change	0.76%	2.46%
Common Stock Issuance & Retirement, Net	$50.70M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net	$401.1M	$0.00
YoY Change		-100.0%
Cash From Financing Activities	$1.234B	-$408.7M
YoY Change	-402.01%	-231.04%
NET CHANGE
Cash From Operating Activities	$2.688B	$1.360B
Cash From Investing Activities	-$1.227B	-$1.391B
Cash From Financing Activities	$1.234B	-$408.7M
Net Change In Cash	$2.696B	-$439.9M
YoY Change	-712.75%	-41.28%
FREE CASH FLOW
Cash From Operating Activities	$2.688B	$1.360B
Capital Expenditures	$127.9M	$117.5M
Free Cash Flow	$2.560B	$1.242B
YoY Change	106.09%	-20.45%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	antm	Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-7500000	USD
CY2017Q1	antm	Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-4200000	USD
CY2016Q1	antm	Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability	-223200000	USD
CY2017Q1	antm	Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability	-245300000	USD
CY2016Q4	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	524600000	USD
CY2017Q1	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	556500000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3622100000	USD
CY2016Q4	antm	Available For Sale Securities Equity Securities Cost Current AvailableForSaleSecuritiesEquitySecuritiesCostCurrent	1076100000	USD
CY2017Q1	antm	Available For Sale Securities Equity Securities Cost Current AvailableForSaleSecuritiesEquitySecuritiesCostCurrent	1390300000	USD
CY2016Q4	antm	Available For Sale Securities Equity Securities Cost Noncurrent AvailableForSaleSecuritiesEquitySecuritiesCostNoncurrent	27200000	USD
CY2016Q1	antm	Present Value Of Contract Liability Debt Issuance Costs Related To Equity Units PresentValueOfContractLiabilityDebtIssuanceCostsRelatedToEquityUnits	300000	USD
CY2016Q1	antm	Quality Improvement And Other Claims Expense QualityImprovementAndOtherClaimsExpense	313600000	USD
CY2017Q1	antm	Quality Improvement And Other Claims Expense QualityImprovementAndOtherClaimsExpense	368900000	USD
CY2016	antm	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.02
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	265074917	shares
CY2017Q1	antm	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.02
CY2017Q1	antm	Available For Sale Securities Equity Securities Cost Noncurrent AvailableForSaleSecuritiesEquitySecuritiesCostNoncurrent	27300000	USD
CY2016Q1	antm	Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset	6600000	USD
CY2017Q1	antm	Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset	500000	USD
CY2016Q1	antm	Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset	186600000	USD
CY2017Q1	antm	Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset	88000000	USD
CY2016Q1	antm	Deferred Net Actuarial Gain Loss Postretirement Benefits DeferredNetActuarialGainLossPostretirementBenefits	-159600000	USD
CY2017Q1	antm	Deferred Net Actuarial Gain Loss Postretirement Benefits DeferredNetActuarialGainLossPostretirementBenefits	-143700000	USD
CY2016Q1	antm	Deferred Prior Service Cost Credit Postretirement Benefit Plans DeferredPriorServiceCostCreditPostretirementBenefitPlans	-70100000	USD
CY2017Q1	antm	Deferred Prior Service Cost Credit Postretirement Benefit Plans DeferredPriorServiceCostCreditPostretirementBenefitPlans	-56300000	USD
CY2016Q1	antm	Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax	380600000	USD
CY2017Q1	antm	Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax	394800000	USD
CY2016Q1	antm	Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset	-247800000	USD
CY2017Q1	antm	Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset	-254800000	USD
CY2017Q1	antm	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Per Share Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPerShareAmount	0.07
CY2017Q1	antm	Gross Premium Tax Rate GrossPremiumTaxRate	0.0235
CY2014Q4	antm	Increase In Stock Repurchase Program Authorization IncreaseInStockRepurchaseProgramAuthorization	5000000000	USD
CY2016Q4	antm	Liability For Future Policy Benefits Current LiabilityForFuturePolicyBenefitsCurrent	71800000	USD
CY2017Q1	antm	Liability For Future Policy Benefits Current LiabilityForFuturePolicyBenefitsCurrent	76200000	USD
CY2016Q1	antm	Netrealizedgainslossesonfinancialinstruments Netrealizedgainslossesonfinancialinstruments	-125100000	USD
CY2017Q1	antm	Netrealizedgainslossesonfinancialinstruments Netrealizedgainslossesonfinancialinstruments	7300000	USD
CY2017Q1	antm	Number Of Counties In Geographical Region Served As Independent Licensee NumberOfCountiesInGeographicalRegionServedAsIndependentLicensee	10	county
CY2017Q1	antm	Number Of Counties In State Of Kansas Company Does Not Serve NumberOfCountiesInStateOfKansasCompanyDoesNotServe	30	county
CY2017Q1	antm	Number Of Medical Members NumberOfMedicalMembers	40600000	medical_member
CY2016Q1	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-2400000	USD
CY2017Q1	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-2300000	USD
CY2016Q1	antm	Payments For Proceeds From Financing Derivatives PaymentsForProceedsFromFinancingDerivatives	237100000	USD
CY2017Q1	antm	Payments For Proceeds From Financing Derivatives PaymentsForProceedsFromFinancingDerivatives	8000000	USD
CY2016Q1	antm	Potentially Dilutive Restricted Stock Units Contingent On Operating Results PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults	500000	shares
CY2017Q1	antm	Potentially Dilutive Restricted Stock Units Contingent On Operating Results PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults	100000	shares
CY2016	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.03
CY2017Q1	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.03
CY2017Q1	antm	Stock Repurchased And Retired During Period Average Price StockRepurchasedAndRetiredDuringPeriodAveragePrice	160.81
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001156039
CY2016Q4	invest	Derivative Notional Amount DerivativeNotionalAmount	16834900000	USD
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	264986210	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Anthem, Inc.
CY2017Q1	dei	Trading Symbol TradingSymbol	ANTM
CY2017Q1	invest	Derivative Notional Amount DerivativeNotionalAmount	19564000000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4014900000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-346600000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2017Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	491000000	USD
CY2016Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	164500000	USD
CY2017Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	149700000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	415600000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	441400000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-151400000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	54200000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	53300000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-4900000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-2700000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-382400000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-267900000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-161800000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities	18300000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities	1500000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities	11700000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities	1000000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8805100000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8893400000	USD
CY2016Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	199700000	USD
CY2017Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	193400000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-1100000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	50400000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	41800000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1700000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000	shares
CY2016Q4	us-gaap	Assets Assets	65083100000	USD
CY2017Q1	us-gaap	Assets Assets	68943500000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	34314900000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	37981800000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	22587700000	USD
CY2017Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	25402000000	USD
CY2016Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	908000000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	811000000	USD
CY2016Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	269200000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	124300000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16991800000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	17694300000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	19187400000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	20355100000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	748600000	USD
CY2016Q4	us-gaap	Ceded Premiums Payable CededPremiumsPayable	539100000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	811000000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	638800000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	686700000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18619700000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	19668400000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	42400000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	28000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	138500000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	96300000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	6220300000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	5567700000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	816000000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	563000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	17163100000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	17949700000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	524400000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	560000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	1468500000	USD
CY2017Q1	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	1813300000	USD
CY2016Q4	us-gaap	Available For Sale Securities Equity Securities Noncurrent AvailableForSaleSecuritiesEquitySecuritiesNoncurrent	31400000	USD
CY2017Q1	us-gaap	Available For Sale Securities Equity Securities Noncurrent AvailableForSaleSecuritiesEquitySecuritiesNoncurrent	32100000	USD
CY2016Q1	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	121400000	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	59800000	USD
CY2016Q1	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	92700000	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	30200000	USD
CY2016Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	3330	securities
CY2017Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	2878	securities
CY2016Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-85400000	USD
CY2017Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-46300000	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	425	securities
CY2017Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	321	securities
CY2016Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	18976500000	USD
CY2017Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	21010900000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2113500000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1676000000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4075300000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6772400000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1546000000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3471200000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-437500000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2697100000	USD
CY2015Q4	us-gaap	Ceded Premiums Payable CededPremiumsPayable	645600000	USD
CY2016Q1	us-gaap	Ceded Premiums Payable CededPremiumsPayable	500200000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	27300000	USD
CY2017Q1	us-gaap	Derivative Asset Collateral Obligation To Return Cash Offset DerivativeAssetCollateralObligationToReturnCashOffset	63300000	USD
CY2016Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	92800000	USD
CY2017Q1	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	162900000	USD
CY2016Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	758700000	USD
CY2017Q1	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	321200000	USD
CY2017Q1	us-gaap	Ceded Premiums Payable CededPremiumsPayable	454300000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.65
CY2017Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.65
CY2016Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.65
CY2017Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.65
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	263747395	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	265074917	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	263747395	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	265074917	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2600000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	2600000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	613200000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1116000000	USD
CY2016Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	73300000	USD
CY2017Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-157200000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	35300000	USD
CY2017Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	34100000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	2600000	USD
CY2017Q1	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	1500000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2779900000	USD
CY2017Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2663900000	USD
CY2016Q1	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-628300000	USD
CY2017Q1	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-648900000	USD
CY2016Q1	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	100000	USD
CY2017Q1	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	700000	USD
CY2016Q4	us-gaap	Deposits Received For Securities Loaned At Carrying Value DepositsReceivedForSecuritiesLoanedAtCarryingValue	1078900000	USD
CY2017Q1	us-gaap	Deposits Received For Securities Loaned At Carrying Value DepositsReceivedForSecuritiesLoanedAtCarryingValue	1233400000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	25600000	USD
CY2016Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	665900000	USD
CY2017Q1	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	158300000	USD
CY2016Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	241900000	USD
CY2017Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	332900000	USD
CY2016Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	149100000	USD
CY2017Q1	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	170000000	USD
CY2016Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-153800000	USD
CY2017Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-10300000	USD
CY2017Q1	us-gaap	Derivative Liability Collateral Right To Reclaim Cash Offset DerivativeLiabilityCollateralRightToReclaimCashOffset	115600000	USD
CY2016Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	92800000	USD
CY2017Q1	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	162900000	USD
CY2016Q1	us-gaap	Dividend Payable Date To Be Paid Day Month And Year DividendPayableDateToBePaidDayMonthAndYear	2016-03-25
CY2017Q1	us-gaap	Dividend Payable Date To Be Paid Day Month And Year DividendPayableDateToBePaidDayMonthAndYear	2017-03-24
CY2016Q1	us-gaap	Dividends Common Stock DividendsCommonStock	171100000	USD
CY2017Q1	us-gaap	Dividends Common Stock DividendsCommonStock	172600000	USD
CY2016Q1	us-gaap	Dividends Payable Date Declared Day Month And Year DividendsPayableDateDeclaredDayMonthAndYear	2016-02-18
CY2017Q1	us-gaap	Dividends Payable Date Declared Day Month And Year DividendsPayableDateDeclaredDayMonthAndYear	2017-02-22
CY2016Q1	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2016-03-10
CY2017Q1	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2017-03-10
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.69
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.82
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.63
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.73
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2400000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1600000	USD
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.464
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.333
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	39800000	USD
CY2017Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	39800000	USD
CY2017Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0	USD
CY2016Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-1700000	USD
CY2017Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-1700000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	1300000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1000000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	-3500000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	3300000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	102200000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	81800000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	3400000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	34500000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	10900000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	20200000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	11900000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	9500000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	1900000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	31200000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	315800000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	411500000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	481400000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	489100000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-200000	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-700000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2850300000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2842700000	USD
CY2016Q4	us-gaap	Good Faith And Margin Deposits With Broker Dealers GoodFaithAndMarginDepositsWithBrokerDealers	405300000	USD
CY2017Q1	us-gaap	Good Faith And Margin Deposits With Broker Dealers GoodFaithAndMarginDepositsWithBrokerDealers	310500000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	17561200000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	17561200000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1312000000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1515000000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1312000000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1515000000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	609000000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	505100000	USD
CY2016Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	104100000	USD
CY2017Q1	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	20000000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	168700000	USD
CY2017Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	66300000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-223800000	USD
CY2016Q1	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	154400000	USD
CY2017Q1	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	154500000	USD
CY2016Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	507700000	USD
CY2017Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	659700000	USD
CY2016Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-27200000	USD
CY2017Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	130100000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	117400000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	205200000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	700000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	46200000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	39500000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	40300000	USD
CY2016Q1	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	-113200000	USD
CY2017Q1	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	-168900000	USD
CY2016Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	170500000	USD
CY2017Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-276300000	USD
CY2016Q1	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	154400000	USD
CY2017Q1	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	154500000	USD
CY2016Q1	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	5300000	USD
CY2017Q1	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	14800000	USD
CY2016Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-124200000	USD
CY2017Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	954200000	USD
CY2016Q1	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	20309400000	USD
CY2017Q1	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	22319500000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7964900000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7923000000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	187100000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	235000000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	39982700000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	42851600000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65083100000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68943500000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21294400000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	23174200000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	241900000	USD
CY2017Q1	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	332900000	USD
CY2015Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	7569800000	USD
CY2016Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	7403100000	USD
CY2016Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	7892600000	USD
CY2017Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	7920600000	USD
CY2016Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	666100000	USD
CY2017Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	673700000	USD
CY2016Q4	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	10185500000	USD
CY2017Q1	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	10308000000	USD
CY2016Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	10626800000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	11772200000	USD
CY2016Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	4619700000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	5288900000	USD
CY2016Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	15225200000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	17173900000	USD
CY2015Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	6924200000	USD
CY2016Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	6902900000	USD
CY2016Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	7353500000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	7466300000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	3500000000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	928400000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1152800000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14358500000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15449900000	USD
CY2017Q1	us-gaap	Loss Contingency Range Of Possible Loss Maximum LossContingencyRangeOfPossibleLossMaximum	250000000	USD
CY2017Q1	us-gaap	Loss Contingency Range Of Possible Loss Minimum LossContingencyRangeOfPossibleLossMinimum	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-408700000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1234300000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1391000000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1227000000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1359800000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2688200000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	703000000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	1009900000	USD
CY2016Q1	us-gaap	Net Investment Income NetInvestmentIncome	171100000	USD
CY2017Q1	us-gaap	Net Investment Income NetInvestmentIncome	207200000	USD
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2017Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	50	states
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1570400000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1585400000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1781800000	USD
CY2017Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1823600000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	467900000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	640500000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	147100000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	94200000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1300000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1400000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-700000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-700000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-89800000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	106100000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-89800000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	106100000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-3800000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-3900000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-25200000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	14000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	13600000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-7500000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	42000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-46600000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-265500000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	17000000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	142900000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-2700000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	172300000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	80200000	USD
CY2016Q1	us-gaap	Other Income OtherIncome	9500000	USD
CY2017Q1	us-gaap	Other Income OtherIncome	5000000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3581300000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3643100000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	883800000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	889900000	USD
CY2016Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	2240500000	USD
CY2017Q1	us-gaap	Other Long Term Investments OtherLongTermInvestments	2287300000	USD
CY2016Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	2221100000	USD
CY2017Q1	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	2311200000	USD
CY2016Q4	us-gaap	Other Receivables OtherReceivables	2536600000	USD
CY2017Q1	us-gaap	Other Receivables OtherReceivables	2445600000	USD
CY2016Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	15800000	USD
CY2017Q1	us-gaap	Other Short Term Investments OtherShortTermInvestments	19600000	USD
CY2016Q1	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Period Increase Decrease OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsPeriodIncreaseDecrease	1700000	USD
CY2017Q1	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Period Increase Decrease OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsPeriodIncreaseDecrease	-3600000	USD
CY2016Q1	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	85200000	USD
CY2017Q1	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	9600000	USD
CY2016Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	-18300000	USD
CY2017Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	-1500000	USD
CY2016Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities	1700000	USD
CY2017Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities	-3600000	USD
CY2016Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	1200000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	4030100000	USD
CY2017Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	-2100000	USD
CY2016Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	66900000	USD
CY2017Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	8100000	USD
CY2016Q4	us-gaap	Payables To Broker Dealers And Clearing Organizations PayablesToBrokerDealersAndClearingOrganizations	93500000	USD
CY2017Q1	us-gaap	Payables To Broker Dealers And Clearing Organizations PayablesToBrokerDealersAndClearingOrganizations	257700000	USD
CY2016Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	15246500000	USD
CY2017Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	17061100000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	600000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	-400000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2017Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-11800000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50700000	USD
CY2016Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	170700000	USD
CY2017Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	172200000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	55500000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	41900000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3287100000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities Equity PaymentsToAcquireAvailableForSaleSecuritiesEquity	747100000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities Equity PaymentsToAcquireAvailableForSaleSecuritiesEquity	367000000	USD
CY2016Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	146400000	USD
CY2017Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	73700000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117500000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	127900000	USD
CY2016Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	15538800000	USD
CY2017Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	17542800000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	5860800000	USD
CY2017Q1	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	5773000000	USD
CY2016Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	18988900000	USD
CY2017Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	20951300000	USD
CY2016Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	249300000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	522700000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-77300000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	401100000	USD
CY2016Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	980000000	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	1719100000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	99300000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	76500000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	3062100000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	3514000000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2507000000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2851800000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	206500000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	63000000	USD
CY2016Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	980000000	USD
CY2017Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1170000000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50900000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	103500000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1977900000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1957600000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1070000000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	157000000	USD
CY2017Q1	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	167800000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	16560600000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	17357700000	USD
CY2016Q1	us-gaap	Revenues Revenues	20288500000	USD
CY2017Q1	us-gaap	Revenues Revenues	22525900000	USD
CY2016Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1311000000	USD
CY2017Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1363200000	USD
CY2016Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	1079800000	USD
CY2017Q1	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	1234900000	USD
CY2016Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	1078900000	USD
CY2017Q1	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	1233400000	USD
CY2016Q4	us-gaap	Securities Received As Collateral SecuritiesReceivedAsCollateral	1079800000	USD
CY2017Q1	us-gaap	Securities Received As Collateral SecuritiesReceivedAsCollateral	1234900000	USD
CY2016Q1	us-gaap	Selling Expense SellingExpense	349900000	USD
CY2017Q1	us-gaap	Selling Expense SellingExpense	348600000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3200200000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3191300000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	37600000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	42700000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	133.09
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1000000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	500000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	131.83
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	166.94
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2100000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1900000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	127.68
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	145.67
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	700000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	109.02
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00491
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00397
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3200
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3200
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0176
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0231
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3100000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	96.31
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	100000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	107.37
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1100000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	30.55
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	40.73
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	254800000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5600000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5500000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	102.80
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	119.24
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	217300000	USD

CY2016Q1

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-7500000

USD

CY2017Q1

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-4200000

USD

CY2016Q1

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-223200000

USD

CY2017Q1

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-245300000

USD

CY2016Q4

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

524600000

USD

CY2017Q1

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

556500000

USD

CY2017Q1

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

3622100000

USD

CY2016Q4

antm

Available For Sale Securities Equity Securities Cost Current

AvailableForSaleSecuritiesEquitySecuritiesCostCurrent

1076100000

USD

CY2017Q1

antm

Available For Sale Securities Equity Securities Cost Current

AvailableForSaleSecuritiesEquitySecuritiesCostCurrent

1390300000

USD

CY2016Q4

antm

Available For Sale Securities Equity Securities Cost Noncurrent

AvailableForSaleSecuritiesEquitySecuritiesCostNoncurrent

27200000

USD

CY2016Q1

antm

Present Value Of Contract Liability Debt Issuance Costs Related To Equity Units

PresentValueOfContractLiabilityDebtIssuanceCostsRelatedToEquityUnits

300000

USD

CY2016Q1

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

313600000

USD

CY2017Q1

antm

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

368900000

USD

CY2016

antm

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2017Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

265074917

shares

CY2017Q1

antm

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2017Q1

antm

Available For Sale Securities Equity Securities Cost Noncurrent

AvailableForSaleSecuritiesEquitySecuritiesCostNoncurrent

27300000

USD

CY2016Q1

antm

Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

6600000

USD

CY2017Q1

antm

Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

500000

USD

CY2016Q1

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

186600000

USD

CY2017Q1

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

88000000

USD

CY2016Q1

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-159600000

USD

CY2017Q1

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-143700000

USD

CY2016Q1

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

-70100000

USD

CY2017Q1

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

-56300000

USD

CY2016Q1

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

380600000

USD

CY2017Q1

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

394800000

USD

CY2016Q1

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-247800000

USD

CY2017Q1

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-254800000

USD

CY2017Q1

antm

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Per Share Amount

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPerShareAmount

0.07

CY2017Q1

antm

Gross Premium Tax Rate

GrossPremiumTaxRate

0.0235

CY2014Q4

antm

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

USD

CY2016Q4

antm

Liability For Future Policy Benefits Current

LiabilityForFuturePolicyBenefitsCurrent

71800000

USD

CY2017Q1

antm

Liability For Future Policy Benefits Current

LiabilityForFuturePolicyBenefitsCurrent

76200000

USD

CY2016Q1

antm

Netrealizedgainslossesonfinancialinstruments

-125100000

USD

CY2017Q1

antm

Netrealizedgainslossesonfinancialinstruments

7300000

USD

CY2017Q1

antm

Number Of Counties In Geographical Region Served As Independent Licensee

NumberOfCountiesInGeographicalRegionServedAsIndependentLicensee

10

county

CY2017Q1

antm

Number Of Counties In State Of Kansas Company Does Not Serve

NumberOfCountiesInStateOfKansasCompanyDoesNotServe

30

county

CY2017Q1

antm

Number Of Medical Members

NumberOfMedicalMembers

40600000

medical_member

CY2016Q1

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-2400000

USD

CY2017Q1

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-2300000

USD

CY2016Q1

antm

Payments For Proceeds From Financing Derivatives

PaymentsForProceedsFromFinancingDerivatives

237100000

USD

CY2017Q1

antm

Payments For Proceeds From Financing Derivatives

PaymentsForProceedsFromFinancingDerivatives

8000000

USD

CY2016Q1

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

500000

shares

CY2017Q1

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

100000

shares

CY2016

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.03

CY2017Q1

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.03

CY2017Q1

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

160.81

CY2017Q1

dei

Amendment Flag

AmendmentFlag

false

CY2017Q1

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2017Q1

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

Q1

CY2017Q1

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2017

CY2017Q1

dei

Document Period End Date

DocumentPeriodEndDate

2017-03-31

CY2017Q1

dei

Document Type

DocumentType

10-Q

CY2017Q1

dei

Entity Central Index Key

EntityCentralIndexKey

0001156039

CY2016Q4

invest

Derivative Notional Amount

DerivativeNotionalAmount

16834900000

USD

CY2017Q2

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

264986210

shares

CY2017Q1

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2017Q1

dei

Entity Registrant Name

EntityRegistrantName

Anthem, Inc.

CY2017Q1

dei

Trading Symbol

TradingSymbol

ANTM

CY2017Q1

invest

Derivative Notional Amount

DerivativeNotionalAmount

19564000000

USD

CY2016Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

4014900000

USD

CY2016Q1

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-346600000

USD

CY2016Q4

us-gaap

Accrued Income Taxes Current

AccruedIncomeTaxesCurrent

0

USD

CY2017Q1

us-gaap

Accrued Income Taxes Current

AccruedIncomeTaxesCurrent

491000000

USD

CY2016Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

164500000

USD

CY2017Q1

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

149700000

USD

CY2016Q1

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

415600000

USD

CY2017Q1

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

441400000

USD

CY2017Q1

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-151400000

USD

CY2016Q1

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

54200000

USD

CY2017Q1

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

53300000

USD

CY2016Q1

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-4900000

USD

CY2017Q1

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2700000

USD

CY2016Q1

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-382400000

USD

CY2016Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-267900000

USD

CY2017Q1

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-161800000

USD

CY2016Q1

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities

18300000

USD

CY2017Q1

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities

1500000

USD

CY2016Q1

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities

11700000

USD

CY2017Q1

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities

1000000

USD

CY2016Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

8805100000

USD

CY2017Q1

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

8893400000

USD

CY2016Q1

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

199700000

USD

CY2017Q1

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

193400000

USD

CY2017Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-1100000

USD

CY2016Q1

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

50400000

USD

CY2017Q1

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

41800000

USD

CY2016Q1

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

1700000

shares

CY2017Q1

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

400000

shares

CY2016Q4

us-gaap

Assets

65083100000

USD

CY2017Q1

us-gaap

Assets

68943500000

USD

CY2016Q4

us-gaap

Assets Current

AssetsCurrent

34314900000

USD

CY2017Q1

us-gaap

Assets Current

AssetsCurrent

37981800000

USD

CY2016Q4

us-gaap

Assets Fair Value Disclosure Recurring

AssetsFairValueDisclosureRecurring

22587700000

USD

CY2017Q1

us-gaap

Assets Fair Value Disclosure Recurring

AssetsFairValueDisclosureRecurring

25402000000

USD

CY2016Q1

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

908000000

USD

CY2017Q1

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

811000000

USD

CY2016Q1

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

269200000

USD

CY2017Q1

us-gaap

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

124300000

USD

CY2016Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

16991800000

USD

CY2017Q1

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

17694300000

USD

CY2016Q4

us-gaap

Available For Sale Securities

AvailableForSaleSecurities

19187400000

USD

CY2017Q1

us-gaap

Available For Sale Securities

AvailableForSaleSecurities

20355100000

USD

CY2016Q4

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

748600000

USD

CY2016Q4

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

539100000

USD

CY2017Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

811000000

USD

CY2016Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

638800000

USD

CY2017Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

686700000

USD

CY2016Q4

us-gaap

Available For Sale Securities Amortized Cost

AvailableForSaleSecuritiesAmortizedCost

18619700000

USD

CY2017Q1

us-gaap

Available For Sale Securities Amortized Cost

AvailableForSaleSecuritiesAmortizedCost

19668400000

USD

CY2016Q4

us-gaap

Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

42400000

USD

CY2017Q1

us-gaap

Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss

AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

28000000

USD

CY2016Q4

us-gaap

Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

138500000

USD

CY2017Q1

us-gaap

Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss

AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss

96300000

USD

CY2016Q4

us-gaap

Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value

AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue

6220300000

USD

CY2017Q1

us-gaap

Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value

AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue

5567700000

USD

CY2016Q4

us-gaap

Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value

AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue

816000000

USD

CY2017Q1

us-gaap

Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value

AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue

563000000

USD

CY2016Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

17163100000

USD

CY2017Q1

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

17949700000

USD

CY2016Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

524400000

USD

CY2017Q1

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

560000000

USD

CY2016Q4

us-gaap

Available For Sale Securities Equity Securities Current

AvailableForSaleSecuritiesEquitySecuritiesCurrent

1468500000

USD

CY2017Q1

us-gaap

Available For Sale Securities Equity Securities Current

AvailableForSaleSecuritiesEquitySecuritiesCurrent

1813300000

USD

CY2016Q4

us-gaap

Available For Sale Securities Equity Securities Noncurrent

AvailableForSaleSecuritiesEquitySecuritiesNoncurrent

31400000

USD

CY2017Q1

us-gaap

Available For Sale Securities Equity Securities Noncurrent

AvailableForSaleSecuritiesEquitySecuritiesNoncurrent

32100000

USD

CY2016Q1

us-gaap

Available For Sale Securities Gross Realized Gains

AvailableForSaleSecuritiesGrossRealizedGains

121400000

USD

CY2017Q1

us-gaap

Available For Sale Securities Gross Realized Gains

AvailableForSaleSecuritiesGrossRealizedGains

59800000

USD

CY2016Q1

us-gaap

Available For Sale Securities Gross Realized Losses

AvailableForSaleSecuritiesGrossRealizedLosses

92700000

USD

CY2017Q1

us-gaap

Available For Sale Securities Gross Realized Losses

AvailableForSaleSecuritiesGrossRealizedLosses

30200000

USD

CY2016Q4

us-gaap

Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year

AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear

3330

securities

CY2017Q1

us-gaap

Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year

AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear

2878

securities

CY2016Q1

us-gaap

Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss

AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss

-85400000

USD

CY2017Q1

us-gaap

Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss

AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss

-46300000

USD

CY2016Q4

us-gaap

Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year

AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear

425

securities

CY2017Q1

us-gaap

Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year

AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear

321

securities

CY2016Q1

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

18976500000

USD

CY2017Q1

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

21010900000

USD

CY2015Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

2113500000

USD

CY2016Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

1676000000

USD

CY2016Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4075300000

USD

CY2017Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

6772400000

USD

CY2016Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

1546000000

USD

CY2017Q1

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

3471200000

USD

CY2016Q1

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

-437500000

USD

CY2017Q1

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

2697100000

USD

CY2015Q4

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

645600000

USD

CY2016Q1

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

500200000

USD

CY2017Q1

us-gaap

Depreciation

27300000

USD

CY2017Q1

us-gaap

Derivative Asset Collateral Obligation To Return Cash Offset

DerivativeAssetCollateralObligationToReturnCashOffset

63300000

USD

CY2016Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

92800000

USD

CY2017Q1

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

162900000

USD

CY2016Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

758700000

USD

CY2017Q1

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

321200000

USD

CY2017Q1

us-gaap

Ceded Premiums Payable

CededPremiumsPayable

454300000

USD

CY2016Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2017Q1

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2016Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.65

CY2017Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.65

CY2016Q1

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

0.65

CY2017Q1

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

0.65

CY2016Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2017Q1

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2016Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2017Q1

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2016Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

263747395

shares

CY2017Q1

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

265074917

shares

CY2016Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

263747395

shares

CY2017Q1

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

265074917

shares

CY2016Q4

us-gaap

Common Stock Value

CommonStockValue

2600000

USD

CY2017Q1

us-gaap

Common Stock Value

CommonStockValue

2600000

USD

CY2016Q1

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

613200000

USD

CY2017Q1

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1116000000

USD

CY2016Q1

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

73300000

USD

CY2017Q1

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-157200000

USD

CY2016Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

35300000

USD

CY2017Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

34100000

USD

CY2016Q1

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

2600000

USD

CY2017Q1

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

1500000

USD

CY2016Q4

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

2779900000

USD

CY2017Q1

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

2663900000

USD

CY2016Q1

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-628300000

USD

CY2017Q1

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-648900000

USD

CY2016Q1

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

100000

USD

CY2017Q1

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

700000

USD

CY2016Q4

us-gaap

Deposits Received For Securities Loaned At Carrying Value

DepositsReceivedForSecuritiesLoanedAtCarryingValue

1078900000

USD

CY2017Q1

us-gaap

Deposits Received For Securities Loaned At Carrying Value

DepositsReceivedForSecuritiesLoanedAtCarryingValue

1233400000

USD

CY2016Q1

us-gaap

Depreciation

25600000

USD

CY2016Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

665900000

USD

CY2017Q1

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

158300000

USD

CY2016Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

241900000

USD

CY2017Q1

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

332900000

USD

CY2016Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

149100000

USD

CY2017Q1

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

170000000

USD

CY2016Q1

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-153800000

USD

CY2017Q1

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-10300000

USD

CY2017Q1

us-gaap

Derivative Liability Collateral Right To Reclaim Cash Offset

DerivativeLiabilityCollateralRightToReclaimCashOffset

115600000

USD

CY2016Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

92800000

USD

CY2017Q1

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

162900000

USD

CY2016Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2016-03-25

CY2017Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2017-03-24

CY2016Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

171100000

USD

CY2017Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

172600000

USD

CY2016Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2016-02-18

CY2017Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2017-02-22

CY2016Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2016-03-10

CY2017Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2017-03-10

CY2016Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

2.69

CY2017Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

3.82

CY2016Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

2.63

CY2017Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

3.73

CY2016Q1

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

2400000

USD

CY2017Q1

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

1600000

USD

CY2016Q1

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.464

CY2017Q1

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.333

CY2016Q1

us-gaap

Excess Tax Benefit From Share Based Compensation Financing Activities

ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

39800000

USD

CY2017Q1

us-gaap

Excess Tax Benefit From Share Based Compensation Financing Activities

ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

0

USD

CY2016Q1

us-gaap

Excess Tax Benefit From Share Based Compensation Operating Activities

ExcessTaxBenefitFromShareBasedCompensationOperatingActivities

39800000

USD

CY2017Q1

us-gaap

Excess Tax Benefit From Share Based Compensation Operating Activities

ExcessTaxBenefitFromShareBasedCompensationOperatingActivities

0

USD

CY2016Q1

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-1700000

USD

CY2017Q1

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-1700000

USD

CY2016Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

1300000

USD

CY2017Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-1000000

USD

CY2016Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-3500000

USD

CY2017Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

3300000

USD

CY2016Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

102200000

USD

CY2017Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

81800000

USD

CY2016Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

3400000

USD

CY2017Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

34500000

USD

CY2016Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

10900000

USD

CY2017Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

20200000

USD

CY2016Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

11900000

USD

CY2017Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

9500000

USD

CY2016Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

1900000

USD

CY2017Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

31200000

USD

CY2015Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

315800000

USD

CY2016Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

411500000

USD

CY2016Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

481400000

USD

CY2017Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

489100000

USD

CY2016Q1

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

-200000

USD

CY2017Q1

us-gaap

Gain Loss On Sale Of Property Plant Equipment

GainLossOnSaleOfPropertyPlantEquipment

-700000

USD

CY2016Q1

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

2850300000

USD

CY2017Q1

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

2842700000

USD

CY2016Q4

us-gaap

Good Faith And Margin Deposits With Broker Dealers

GoodFaithAndMarginDepositsWithBrokerDealers

405300000

USD

CY2017Q1

us-gaap

Good Faith And Margin Deposits With Broker Dealers

GoodFaithAndMarginDepositsWithBrokerDealers

310500000

USD

CY2016Q4

us-gaap

Goodwill

17561200000

USD

CY2017Q1

us-gaap

Goodwill

17561200000

USD

CY2016Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1312000000

USD

CY2017Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1515000000

USD

CY2016Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

1312000000

USD

CY2017Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

1515000000

USD

CY2016Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

609000000

USD

CY2017Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

505100000

USD

CY2016Q1

us-gaap

Income Tax Reconciliation Nondeductible Expense

IncomeTaxReconciliationNondeductibleExpense

104100000

USD

CY2017Q1

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

20000000

USD

CY2016Q4

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

168700000

USD

CY2017Q1

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

0

USD

CY2016Q1

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

66300000

USD

CY2017Q1

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-223800000

USD

CY2016Q1

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

154400000

USD

CY2017Q1

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

154500000

USD

CY2016Q1

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

507700000

USD

CY2017Q1

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

659700000

USD

CY2016Q1

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

-27200000

USD

CY2017Q1

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

130100000

USD

CY2016Q1

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

117400000

USD

CY2017Q1

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

205200000

USD

CY2016Q1

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

700000

USD

CY2017Q1

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

46200000

USD

CY2016Q1

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

39500000

USD

CY2017Q1

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

40300000

USD

CY2016Q1

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-113200000

USD

CY2017Q1

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-168900000

USD

CY2016Q1

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

170500000

USD

CY2017Q1

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

-276300000

USD

CY2016Q1

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

154400000

USD

CY2017Q1

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

154500000

USD

CY2016Q1

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

5300000

USD

CY2017Q1

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

14800000

USD

CY2016Q1

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

-124200000

USD

CY2017Q1

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

954200000

USD

CY2016Q1

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

20309400000

USD

CY2017Q1

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

22319500000

USD

CY2016Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

7964900000

USD

CY2017Q1

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

7923000000

USD

CY2016Q1

us-gaap

Interest Expense

InterestExpense

187100000

USD

CY2017Q1

us-gaap

Interest Expense

InterestExpense

235000000

USD

CY2016Q4

us-gaap

Liabilities

39982700000

USD

CY2017Q1

us-gaap

Liabilities

42851600000

USD

CY2016Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

65083100000

USD

CY2017Q1

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

68943500000

USD

CY2016Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

21294400000

USD

CY2017Q1

us-gaap

Liabilities Current

LiabilitiesCurrent

23174200000

USD

CY2016Q4

us-gaap

Liabilities Fair Value Disclosure Recurring

LiabilitiesFairValueDisclosureRecurring

241900000

USD

CY2017Q1

us-gaap

Liabilities Fair Value Disclosure Recurring

LiabilitiesFairValueDisclosureRecurring

332900000

USD

CY2015Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

7569800000

USD

CY2016Q1

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

7403100000

USD

CY2016Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

7892600000

USD

CY2017Q1

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

7920600000

USD

CY2016Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

666100000

USD

CY2017Q1

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

673700000

USD

CY2016Q4

us-gaap

Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense

LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense

10185500000

USD

CY2017Q1

us-gaap

Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense

LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense

10308000000

USD

CY2016Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

10626800000

USD

CY2017Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

11772200000

USD

CY2016Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

4619700000

USD

CY2017Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

5288900000

USD

CY2016Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

15225200000

USD

CY2017Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

17173900000

USD

CY2015Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

6924200000

USD

CY2016Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

6902900000

USD

CY2016Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

7353500000

USD

CY2017Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

7466300000

USD

CY2017Q1

us-gaap

Line Of Credit Facility Maximum Borrowing Capacity

LineOfCreditFacilityMaximumBorrowingCapacity

3500000000

USD

CY2016Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

928400000

USD

CY2017Q1

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1152800000

USD

CY2016Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

14358500000

USD

CY2017Q1

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

15449900000

USD

CY2017Q1

us-gaap

Loss Contingency Range Of Possible Loss Maximum

LossContingencyRangeOfPossibleLossMaximum

250000000

USD

CY2017Q1

us-gaap

Loss Contingency Range Of Possible Loss Minimum

LossContingencyRangeOfPossibleLossMinimum

0

USD

CY2016Q1

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-408700000

USD

CY2017Q1

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

1234300000

USD

CY2016Q1

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-1391000000

USD

CY2017Q1

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-1227000000

USD

CY2016Q1

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

1359800000

USD

CY2017Q1

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

2688200000

USD

CY2016Q1

us-gaap

Net Income Loss

NetIncomeLoss

703000000

USD

CY2017Q1

us-gaap

Net Income Loss

NetIncomeLoss

1009900000

USD

CY2016Q1

us-gaap

Net Investment Income

NetInvestmentIncome

171100000

USD

CY2017Q1

us-gaap

Net Investment Income

NetInvestmentIncome

207200000

USD

CY2017Q1

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

3

segment

CY2017Q1

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

states

CY2016Q1

us-gaap

Operating Income Loss

OperatingIncomeLoss

1570400000

USD

CY2017Q1

us-gaap

Operating Income Loss

OperatingIncomeLoss

1585400000

USD

CY2016Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

1781800000

USD

CY2017Q1

us-gaap

Other Assets Current

OtherAssetsCurrent

1823600000

USD

CY2016Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

467900000

USD

CY2017Q1

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

640500000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

147100000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

94200000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

1300000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

1400000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

-700000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

-700000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-89800000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

106100000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-89800000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

106100000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-3800000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-3900000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

-25200000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

14000000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

13600000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

-7500000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

42000000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-46600000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

-265500000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

17000000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

142900000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

-2700000

USD

CY2016Q1

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

172300000

USD

CY2017Q1

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

80200000

USD

CY2016Q1

us-gaap

Other Income

OtherIncome

9500000

USD

CY2017Q1

us-gaap

Other Income

OtherIncome

5000000

USD

CY2016Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

3581300000

USD

CY2017Q1

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

3643100000

USD

CY2016Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

883800000

USD

CY2017Q1

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

889900000

USD

CY2016Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

2240500000

USD

CY2017Q1

us-gaap

Other Long Term Investments

OtherLongTermInvestments

2287300000

USD

CY2016Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

2221100000

USD

CY2017Q1

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

2311200000

USD

CY2016Q4

us-gaap

Other Receivables

OtherReceivables

2536600000

USD

CY2017Q1

us-gaap

Other Receivables

OtherReceivables

2445600000

USD

CY2016Q4

us-gaap

Other Short Term Investments

OtherShortTermInvestments

15800000

USD

CY2017Q1

us-gaap

Other Short Term Investments

OtherShortTermInvestments

19600000

USD

CY2016Q1

us-gaap

Other Than Temporary Impairment Credit Losses Recognized In Earnings Period Increase Decrease

OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsPeriodIncreaseDecrease

1700000

USD

CY2017Q1

us-gaap

Other Than Temporary Impairment Credit Losses Recognized In Earnings Period Increase Decrease

OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsPeriodIncreaseDecrease

-3600000

USD

CY2016Q1

us-gaap

Other Than Temporary Impairment Losses Investments Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

85200000

USD

CY2017Q1

us-gaap

Other Than Temporary Impairment Losses Investments Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

9600000

USD

CY2016Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

-18300000

USD

CY2017Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

-1500000

USD

CY2016Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities

1700000

USD

CY2017Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities

-3600000

USD

CY2016Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

1200000

USD

CY2017Q1

us-gaap

Payments To Acquire Available For Sale Securities Debt

PaymentsToAcquireAvailableForSaleSecuritiesDebt

4030100000

USD

CY2017Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

-2100000

USD

CY2016Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

66900000

USD

CY2017Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

8100000

USD

CY2016Q4

us-gaap

Payables To Broker Dealers And Clearing Organizations

PayablesToBrokerDealersAndClearingOrganizations

93500000

USD

CY2017Q1

us-gaap

Payables To Broker Dealers And Clearing Organizations

PayablesToBrokerDealersAndClearingOrganizations

257700000

USD

CY2016Q1

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

15246500000

USD

CY2017Q1

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

17061100000

USD

CY2016Q1

us-gaap

Payments For Proceeds From Derivative Instrument Investing Activities

PaymentsForProceedsFromDerivativeInstrumentInvestingActivities

600000

USD

CY2017Q1

us-gaap

Payments For Proceeds From Derivative Instrument Investing Activities

PaymentsForProceedsFromDerivativeInstrumentInvestingActivities

-400000

USD

CY2016Q1

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

0

USD

CY2017Q1

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-11800000

USD

CY2016Q1

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

USD

CY2017Q1

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

50700000

USD

CY2016Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

170700000

USD

CY2017Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

172200000

USD

CY2016Q1

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

55500000

USD

CY2017Q1

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

41900000

USD

CY2016Q1

us-gaap

Payments To Acquire Available For Sale Securities Debt

PaymentsToAcquireAvailableForSaleSecuritiesDebt

3287100000

USD

CY2016Q1

us-gaap

Payments To Acquire Available For Sale Securities Equity

PaymentsToAcquireAvailableForSaleSecuritiesEquity

747100000

USD

CY2017Q1

us-gaap

Payments To Acquire Available For Sale Securities Equity

PaymentsToAcquireAvailableForSaleSecuritiesEquity

367000000

USD

CY2016Q1

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

146400000

USD

CY2017Q1

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

73700000

USD

CY2016Q1

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

117500000

USD

CY2017Q1

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

127900000

USD

CY2016Q1

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

15538800000

USD

CY2017Q1

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

17542800000

USD

CY2016Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2017Q1

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2016Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2017Q1

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2016Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2017Q1

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2016Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2017Q1

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2016Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2017Q1

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2016Q4

us-gaap

Premiums And Other Receivables Net

PremiumsAndOtherReceivablesNet

5860800000

USD

CY2017Q1

us-gaap

Premiums And Other Receivables Net

PremiumsAndOtherReceivablesNet

5773000000

USD

CY2016Q1

us-gaap

Premiums Earned Net

PremiumsEarnedNet

18988900000

USD

CY2017Q1

us-gaap

Premiums Earned Net

PremiumsEarnedNet

20951300000

USD

CY2016Q1

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

249300000

USD

CY2017Q1

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

522700000

USD

CY2016Q1

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-77300000

USD

CY2017Q1

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

401100000

USD

CY2016Q1

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

980000000

USD

CY2017Q1

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

1719100000

USD

CY2016Q1

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

99300000

USD

CY2017Q1

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

76500000

USD

CY2016Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

3062100000

USD

CY2017Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

3514000000

USD

CY2016Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

2507000000

USD

CY2017Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

2851800000

USD

CY2016Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities Equity

ProceedsFromSaleOfAvailableForSaleSecuritiesEquity

206500000

USD

CY2017Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities Equity

ProceedsFromSaleOfAvailableForSaleSecuritiesEquity

63000000

USD

CY2016Q1

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

980000000

USD

CY2017Q1

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

1170000000

USD

CY2016Q1

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

50900000

USD

CY2017Q1

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

103500000

USD

CY2016Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

1977900000

USD

CY2017Q1

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

1957600000

USD

CY2016Q1

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

0

USD

CY2017Q1

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1070000000

USD

CY2016Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

157000000

USD

CY2017Q1

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

167800000

USD

CY2016Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

16560600000

USD

CY2017Q1

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

17357700000

USD

CY2016Q1

us-gaap

Revenues

20288500000

USD

CY2017Q1

us-gaap

Revenues

22525900000

USD

CY2016Q1

us-gaap

Sales Revenue Services Net

SalesRevenueServicesNet

1311000000

USD

CY2017Q1

us-gaap

Sales Revenue Services Net

SalesRevenueServicesNet

1363200000

USD

CY2016Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

1079800000

USD

CY2017Q1

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

1234900000

USD

CY2016Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

1078900000

USD

CY2017Q1

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

1233400000

USD

CY2016Q4

us-gaap

Securities Received As Collateral

SecuritiesReceivedAsCollateral

1079800000

USD

CY2017Q1

us-gaap

Securities Received As Collateral

SecuritiesReceivedAsCollateral

1234900000

USD

CY2016Q1

us-gaap

Selling Expense

SellingExpense

349900000

USD

CY2017Q1

us-gaap

Selling Expense

SellingExpense

348600000

USD

CY2016Q1

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

3200200000

USD

CY2017Q1

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

3191300000

USD

CY2016Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

37600000

USD

CY2017Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

42700000

USD

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

0

shares

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

133.09

CY2016Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

1000000

shares

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

500000

shares

CY2016Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

131.83

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

166.94

CY2016Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

2100000

shares

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1900000

shares

CY2016Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

127.68

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

145.67

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

700000

shares

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

109.02

CY2016Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00491

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00397

CY2016Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.3200

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.3200

CY2016Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0176

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0231

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

3100000

shares

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

96.31

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

107.37

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

1100000

shares

CY2016Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

30.55

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

40.73

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

254800000

USD

CY2016Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

5600000

shares

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

5500000

shares

CY2016Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

102.80

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

119.24

CY2017Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

217300000

USD

CY2017Q1

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

83.14

CY2017Q1

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

166.95

CY2016Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y1M5D

CY2017Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y0M0D

CY2017Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P4Y7M0D

CY2017Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y6M8D

CY2016Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

440000000

USD

CY2017Q1

us-gaap

Short Term Borrowings

ShortTermBorrowings

540000000

USD

CY2017Q1

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

1100000

shares

CY2016Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

60600000

USD

CY2017Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

99900000

USD

CY2017Q1

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

4125200000

USD

CY2017Q1

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

300000

shares

CY2017Q1

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

50700000

USD

CY2015Q4

us-gaap

Stockholders Equity

StockholdersEquity

23044100000

USD

CY2016Q1

us-gaap

Stockholders Equity

StockholdersEquity

23547100000

USD

CY2016Q4

us-gaap

Stockholders Equity

StockholdersEquity

25100400000

USD

CY2017Q1

us-gaap

Stockholders Equity

StockholdersEquity

26091900000

USD

CY2016Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

15979200000

USD

CY2017Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

17968500000

USD

CY2016Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

754000000

USD

CY2017Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

794600000

USD

CY2016Q4

us-gaap

Unearned Premiums

UnearnedPremiums

971900000

USD

CY2017Q1

us-gaap

Unearned Premiums

UnearnedPremiums

1926100000

USD

CY2016Q1

us-gaap

Unrealized Gain Loss On Cash Flow Hedging Instruments

UnrealizedGainLossOnCashFlowHedgingInstruments

-533200000

USD

CY2017Q1

us-gaap

Unrealized Gain Loss On Cash Flow Hedging Instruments

UnrealizedGainLossOnCashFlowHedgingInstruments

-239400000

USD

CY2016Q1

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

5700000

shares

CY2017Q1

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

6000000

shares

CY2016Q1

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

267500000

shares

CY2017Q1

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

270400000

shares

CY2016Q1

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

261800000

shares

CY2017Q1

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

264400000

shares

CY2017Q1

us-gaap

Description Of New Accounting Pronouncements Not Yet Adopted

DescriptionOfNewAccountingPronouncementsNotYetAdopted

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted: </font><font style="font-family:inherit;font-size:10pt;">In March 2017, the FASB issued Accounting Standards Update No. 2017-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font><font style="font-family:inherit;font-size:10pt;">, or ASU 2017-07. This amendment requires entities to disaggregate the service cost component from the other components of the benefit cost and present the service cost component in the same income statement line item as other employee compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. In addition, the amendment allows only the service cost component to be eligible for asset capitalization. Upon adoption, the guidance on the presentation of the components of net periodic benefit cost in the income statement is to be applied retrospectively and the guidance limiting the capitalization of net periodic benefit cost in assets to the service cost component is to be applied prospectively. ASU 2017-07 is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. We are currently evaluating the effects the adoption of ASU 2017-07 will have upon our consolidated financial position, results of operations and cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued Accounting Standards Update No. 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">, or ASU 2017-04. This amendment removes Step 2 of the goodwill impairment test under current guidance which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value. Upon adoption, the guidance is to be applied prospectively. ASU 2017-04 is effective for us on January 1, 2020, with early adoption permitted. The adoption of ASU 2017-04 is not expected to have a material impact on our consolidated financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no other new accounting pronouncements that were issued or became effective since the issuance of our </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.</font></div></div>

CY2017Q1

us-gaap

Nature Of Operations

NatureOfOperations

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">References to the terms “we”, “our”, “us”, “Anthem” or the “Company” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. </font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are one of the largest health benefits companies in the United States in terms of medical membership, serving </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">40.6</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">medical members through our affiliated health plans as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. We offer a broad spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Our managed care plans include: preferred provider organizations, or PPOs; health maintenance organizations, or HMOs; point-of-service, or POS, plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans, or CDHPs; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal health care. We also provide services to the federal government in connection with the Federal Employee Program, or FEP. </font></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;"> counties in the Kansas City area), Nevada, New Hampshire, New York (as BCBS in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10</font><font style="font-family:inherit;font-size:10pt;"> New York City metropolitan and surrounding counties, and as Blue Cross or BCBS in selected upstate counties), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of Georgia, and Empire Blue Cross Blue Shield or Empire Blue Cross (in our New York service areas). We also conduct business through arrangements with other BCBS licensees in South Carolina and western New York. Through our AMERIGROUP Corporation, or Amerigroup, subsidiary, we conduct business in Florida, Georgia, Iowa, Kansas, Louisiana, Maryland, Nevada, New Jersey, New Mexico, New York, Tennessee, Texas and Washington. In addition, we conduct business through our Simply Healthcare </font><font style="font-family:inherit;font-size:10pt;">Holdings, Inc., or Simply Healthcare, </font><font style="font-family:inherit;font-size:10pt;">subsidiary in Florida. We also serve customers throughout the country as HealthLink, UniCare (including a non-risk arrangement with Massachusetts), and in certain Arizona, California, Nevada and Virginia markets through our CareMore Health Group, Inc., or CareMore, subsidiary. We are licensed to conduct insurance operations in all </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50</font><font style="font-family:inherit;font-size:10pt;"> states through our subsidiaries.</font></div></div>

CY2017Q1

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, "Segment Information"), for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,267.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,625.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,892.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(521.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(539.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,745.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,607.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,353.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,084.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,884.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,968.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods redundancies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(334.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(460.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(794.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,750.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,423.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,173.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net payments attributable to:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,560.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,212.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,772.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,062.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,226.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,288.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,622.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,438.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,061.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,593.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,466.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,312.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,607.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,920.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was </font><font style="font-family:inherit;font-size:10pt;">$93.1</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$255.9</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,524.1</font><font style="font-family:inherit;font-size:10pt;"> for the claim years 2015 and prior, 2016 and 2017 respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was </font><font style="font-family:inherit;font-size:10pt;">$55.6</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$865.2</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3,672.4</font><font style="font-family:inherit;font-size:10pt;"> for the claim years 2015 and prior, 2016 and 2017, respectively.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, "Segment Information"), for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,396.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,173.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,569.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(635.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(645.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,760.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,163.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,924.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,520.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,459.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,979.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods redundancies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(439.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(314.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(754.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,081.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,144.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,225.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net payments attributable to:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,582.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,044.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,626.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,619.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,205.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,041.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,246.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,636.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,266.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,902.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">488.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,124.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,278.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,403.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

Name	View Source	Status
0001156039-17-000005-index-headers.html	Edgar Link	pending
0001156039-17-000005-index.html	Edgar Link	pending
0001156039-17-000005.txt	Edgar Link	pending
0001156039-17-000005-xbrl.zip	Edgar Link	pending
antm-20170331.xml	Edgar Link	completed
antm-20170331.xsd	Edgar Link	pending
antm-20170331x10qforq1.htm	Edgar Link	pending
antm-20170331_cal.xml	Edgar Link	unprocessable
antm-20170331_def.xml	Edgar Link	unprocessable
antm-20170331_lab.xml	Edgar Link	unprocessable
antm-20170331_pre.xml	Edgar Link	unprocessable
exhibit311-20170331forq1.htm	Edgar Link	pending
exhibit312-20170331forq1.htm	Edgar Link	pending
exhibit321-20170331forq1.htm	Edgar Link	pending
exhibit322-20170331forq1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2017 Q1 Form 10-Q Financial Statement

#000115603917000005 Filed on April 26, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2017 Q1 Form 10-Q Financial Statement

#000115603917000005 Filed on April 26, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv